- Home
- SNES vs PHIO Comparison
SNES vs PHIO Comparison
Compare SNES & PHIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNES
- PHIO
- Stock Information
- Founded
- SNES 2004
- PHIO 2011
- Country
- SNES United States
- PHIO United States
- Employees
- SNES N/A
- PHIO N/A
- Industry
- SNES Agricultural Chemicals
- PHIO Biotechnology: Pharmaceutical Preparations
- Sector
- SNES Industrials
- PHIO Health Care
- Exchange
- SNES Nasdaq
- PHIO Nasdaq
- Market Cap
- SNES 2.3M
- PHIO 2.3M
- IPO Year
- SNES 2016
- PHIO N/A
- Fundamental
- Price
- SNES $3.16
- PHIO $2.61
- Analyst Decision
- SNES Strong Buy
- PHIO Strong Buy
- Analyst Count
- SNES 1
- PHIO 1
- Target Price
- SNES $10.00
- PHIO $36.00
- AVG Volume (30 Days)
- SNES 311.7K
- PHIO 30.8K
- Earning Date
- SNES 11-12-2024
- PHIO 11-14-2024
- Dividend Yield
- SNES N/A
- PHIO N/A
- EPS Growth
- SNES N/A
- PHIO N/A
- EPS
- SNES N/A
- PHIO N/A
- Revenue
- SNES $1,651,000.00
- PHIO N/A
- Revenue This Year
- SNES $91.45
- PHIO N/A
- Revenue Next Year
- SNES $101.31
- PHIO N/A
- P/E Ratio
- SNES N/A
- PHIO N/A
- Revenue Growth
- SNES 38.16
- PHIO N/A
- 52 Week Low
- SNES $1.90
- PHIO $2.17
- 52 Week High
- SNES $21.40
- PHIO $10.35
- Technical
- Relative Strength Index (RSI)
- SNES 56.47
- PHIO 48.74
- Support Level
- SNES $2.32
- PHIO $2.58
- Resistance Level
- SNES $5.00
- PHIO $2.91
- Average True Range (ATR)
- SNES 0.52
- PHIO 0.21
- MACD
- SNES 0.13
- PHIO 0.01
- Stochastic Oscillator
- SNES 35.66
- PHIO 26.76
About SNES SenesTech Inc.
SenesTech Inc is a United States-based biotech platform and research company engaged in developing technology for managing animal pest populations through fertility control. The company provides its solutions to the animal market, commercial markets, and food markets. It currently has two product lines of fertility control products: ContraPest and Evolve.
About PHIO Phio Pharmaceuticals Corp.
Phio Pharmaceuticals Corp is a clinical-stage biotechnology company whose proprietary INTASYL self-delivering RNAi technology platform is designed to make immune cells more effective in killing tumor cells. The Company is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems.